Health Advance, Inc. has reached a deal with Micro Medtech, Ltd. for exclusive licensing rights in North America to cebidiofen and polyoxyfen, two patent-pending product formulations for pharmaceutical foods made from Ibuprofen and botanical extract blends containing cannabidiol, mitragyna speciose, and kava.

The two companies will begin working together with health claim experts Nutrasource Diagnostics, Inc. to conduct a review and product development plan to determine claims and optimal commercialization strategies for cebidiofen and polyoxyfen. The formulas are specifically tied to the production of the neurotransmitters that enable management and enhancement to sensory response to pain and inflammation, formulated by ingredients that are classified as Generally Recognized as Safe (GRAS) by the FDA.

The Product Development Plan process for both (provisional) patent-pending product formulations will take six to eight weeks to complete from the start date that will commence in March. The plans will identify current gaps in the research and outline the clinical and regulatory pathways going forward.

Based upon the results of the plans for cebidiofen (primarily derived from cannabidiol fiber extract) and polyoxyfen (primarily derived from mitragyna speciose, also known as kratom), the requisite clinical studies and product testing will be conducted to meet the regulatory, clinical and manufacturing requirements for commercialization.